🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

7,888 results for “1” Clear

  1. ATI-501 400mg BID (Low dose)

    Aclaris Therapeutics

    Alopecia

    phase 2 small molecule completed

    1 trial

  2. ATRN-119

    Aprea Therapeutics

    Advanced Solid Tumor

    phase 2 small molecule active

    1 trial

  3. ATRN-119

    Aprea Therapeutics

    HPV Positive Oropharyngeal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  4. AU-011

    Aura Biosciences

    Uveal Melanoma

    phase 2 small molecule completed

    1 trial

  5. AU-011

    Aura Biosciences

    Eye Cancer

    phase 2 small molecule active

    1 trial

  6. AUR103 Calcium

    Disc Medicine

    HER 2 Positive Gastric Cancer

    phase 2 small molecule terminated

    1 trial

  7. AUTO CAR T cell therapy

    Autolus GmbH

    Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy

    phase 2 mab active

    1 trial

  8. AUTO1

    Autolus GmbH

    Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia

    phase 2 mab active

    2 trials

  9. AUTO1, Cyclophosphamide 500 mg Powder for Solution for Injection or Infusion, Fludara 50 mg powder for solution for injection or infusion

    Autolus GmbH

    Systemic Lupus Erythematosus with Active Lupus Nephritis

    phase 2 small molecule active

    1 trial

  10. AUTO1, MabThera 500 mg concentrate for solution for infusion, AUTO4, MabThera 100 mg concentrate for solution for infusion

    Autolus GmbH

    Potential malignancy in patients who received treatment with Autolus CAR T cell therapy.

    phase 2 small molecule active

    1 trial

  11. AUTO3 (CD19/22 CAR T cells

    Autolus GmbH

    B Acute Lymphoblastic Leukemia

    phase 2 mab completed

    1 trial

  12. AUTOLOGOUS DENDRITIC CELLS LOADED WITH AUTOLOGOUS TUMOR LYSATE, Tecentriq 1 200 mg concentrate for solution for infusion

    The George Institute

    Lung Cancer

    phase 2 small molecule active

    1 trial

  13. AV-101

    Vistagen Therapeutics

    Parkinson Disease

    phase 2 small molecule active

    1 trial

  14. AV-101

    Vistagen Therapeutics

    Major Depressive Disorder

    phase 2 small molecule completed

    1 trial

  15. AVELUMAB, Erbitux 5 mg/mL solution for infusion

    Fondazione Telethon ETS

    recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)

    phase 2 small molecule active

    1 trial

  16. AVI-5126

    Sarepta Therapeutics

    Cardiovascular Disease

    phase 2 small molecule terminated

    1 trial

  17. AVTX-009 Regimen 1

    Avalo Therapeutics

    Hidradenitis Suppurativa

    phase 2 small molecule completed

    1 trial

  18. AVTX-801

    Ultragenyx UK Limited

    SLC35A2-CDG - Solute Carrier Family 35 Member A2 Congenital Disorder of Glycosylation

    phase 2 small molecule active

    1 trial

  19. AZACITIDINE

    Blueprint Medicines (Netherlands) B.V.

    Advanced Systemic Mastocytosis

    phase 2 small molecule active

    1 trial

  20. AZACITIDINE

    ALX ONCOLOGY HOLDINGS INC

    Patients with higher risk myelodysplastic syndrome (MDS) who have not yet been treated for their disease

    phase 2 small molecule active

    1 trial

  21. AZD0022, AZD0022, Erbitux 5 mg/mL solution for infusion

    AstraZeneca AB

    Non Small Cell Lung Cancer Colorectal Cancer Pancreatic Ductal Adenocarcinoma

    phase 2 small molecule active

    1 trial

  22. AZD0486, AZD0486, TOCILIZUMAB

    AstraZeneca AB

    B-Cell Acute Lymphoblastic Leukaemia

    phase 2 small molecule active

    1 trial

  23. AZD0516, AZD9574, AZD9574, AZD9574, AZD9574

    AstraZeneca AB

    Metastatic Prostate Cancer

    phase 2 small molecule active

    1 trial

  24. AZD0901, Rilvegostomig, DS-8201a

    AstraZeneca AB

    Locally Advanced Resectable Gastroesophageal Adenocarcinoma

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources